SPIKE GLYCOPROTEIN (SARS-COV-2)

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 16:52:41 UTC 2023` Edited by `admin` on `Sat Dec 16 16:52:41 UTC 2023`
Protein Type	VIRAL STRUCTURAL PROTEIN
Protein Sub Type	VIRAL ENVELOPE PROTEIN
Sequence Origin	VIRAL
Sequence Type	COMPLETE
Record UNII	8R39BE7TJJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SPIKE GLYCOPROTEIN (SARS-COV-2)

Common Name

English

E2 (SARS-COV-2)

Common Name

English

PEPLOMER PROTEIN (SARS-COV-2)

Common Name

English

S GLYCOPROTEIN (SARS-COV-2)

Common Name

English

Code System Code Type Description

FDA UNII

8R39BE7TJJ

Created by admin on Sat Dec 16 16:52:41 UTC 2023 , Edited by admin on Sat Dec 16 16:52:41 UTC 2023

PRIMARY

From	To
1_1069	1_1113
3_1069	3_1113
2_1069	2_1113
1_1019	1_1030
3_1019	3_1030
2_1019	2_1030
1_827	1_838
3_827	3_838
2_827	2_838
1_730	1_736
3_730	3_736
2_730	2_736
1_725	1_747
3_725	3_747
2_725	2_747
1_649	1_658
3_649	3_658
2_649	2_658
1_604	1_636
3_604	3_636
2_604	2_636
1_525	1_577
3_525	3_577
2_525	2_577
1_467	1_475
3_467	3_475
2_467	2_475
1_378	1_512
3_378	3_512
2_378	2_512
1_366	1_419
3_366	3_419
2_366	2_419
1_323	1_348
3_323	3_348
2_323	2_348
1_278	1_288
3_278	3_288
2_278	2_288
1_118	1_153
3_118	3_153
2_118	2_153
1_2	1_123
3_2	3_123
2_2	2_123

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_4
N	1_48
N	1_61
N	1_109
N	1_136
N	1_152
N	1_221
N	1_269
N	1_318
N	1_330
N	1_590
N	1_603
N	1_644
N	1_696
N	1_704
N	1_788
N	1_1061
N	1_1085
N	1_1121
N	1_1145
N	1_1160
N	1_1181
N	2_4
N	2_48
N	2_61
N	2_109
N	2_136
N	2_152
N	2_221
N	2_269
N	2_318
N	2_330
N	2_590
N	2_603
N	2_644
N	2_696
N	2_704
N	2_788
N	2_1061
N	2_1085
N	2_1121
N	2_1145
N	2_1160
N	2_1181
N	3_4
N	3_48
N	3_61
N	3_109
N	3_136
N	3_152
N	3_221
N	3_269
N	3_318
N	3_330
N	3_590
N	3_603
N	3_644
N	3_696
N	3_704
N	3_788
N	3_1061
N	3_1085
N	3_1121
N	3_1145
N	3_1160
N	3_1181
O	1_310
O	1_312
O	2_310
O	2_312
O	3_310
O	3_312

Related Record Type Details


					PV6AA88RDU

ENSOVIBEP

LIGAND->TARGET

Amount:


					I0BGE6P6I6

REGDANVIMAB

INHIBITOR -> TARGET

Interaction Type:

BINDING

Amount:


					2AD5KH3SE4

AMUBARVIMAB

INHIBITOR -> TARGET

Interaction Type:

BINDING

Amount:


					054Q5D7VZI

ADINTREVIMAB

LIGAND->TARGET

Comments:

Binding studies have demonstrated that ADG20 competes with ACE-2 for binding to SARS-CoV-2 S protein thus preventing viral entry

Amount:


					JVG3CC2YJ4

CVXGA1

VECTOR->EXPRESSED PROTEIN

Amount:


					SM01RRU9KK

ROMLUSEVIMAB

INHIBITOR -> TARGET

Comments:

BRII-198 has no or moderately reduced binding activity (approximately two to three-fold) to human Fc receptors (FcR I, FcR IIa, FcR IIb, FcR IIIa.

Interaction Type:

BINDING

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL